Condition: Acute Myeloid Leukemia · Myelodysplastic Syndrome With Excess Blasts-2 · Sponsor: Eric Stephen Winer, MD
The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701
This description comes directly from the study's public registry record.
Eric S Winer, MD · 1 617-632-2053 · erics_winer@dfci.harvard.edu
Eric S Winter, MD · 1 617-632-2053 · erics_winer@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05703542